Leqembi is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Leqembi is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameLeqembi
Authorized genericlecanemab
Regular genericlecanemab
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Leqembi?
The original
–
–

Brand nameThe maker’s card

LEQEMBI Copay Assistance Program

Savings card from Eisai

No insuranceNeeds insuranceNo cash price listed.
Insurance $0 per date of treatment

The card takes up to $10,000 a year off your co-pay.

Sign up on eisaipatientsupport.com 

Or call 1-833-453-7362.

In the maker’s words

“little as $0 out-of-pocket per date of treatment.”

From the maker’s offer on eisaipatientsupport.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Leqembi itself, from the same company, sold without the brand name, and usually for less. For now Leqembi is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Leqembi is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Source: the FDA label for Leqembi (Eisai Inc.), July 21, 2026. Full label on DailyMed 

Good to know